A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary aim of this study is allow the patients suffering from Crohn's disease , who both
completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from
the treatment, to receive treatment with certolizumab pegol until the drug is available for
the Crohn's disease indication in Greece.